MADISON, WI, January 08, 2014 /24-7PressRelease/ -- Scientists from AhR Pharmaceuticals, Inc. and University of Wisconsin-Madison have jointly published a peer-reviewed scientific article in the journal Cancer Letters documenting ITE's capability of inhibiting cell proliferation and migration of human ovarian cancer cells in cell culture systems and obstructing growth of cancer tissues derived from a human ovarian cancer cell line in a whole animal modeling system.
ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor. Once binding to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community, as well, have demonstrated ITE's potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems.
Leading the research efforts of AhR Pharmaceuticals' on ITE's therapeutic potentials is Dr. Jiasheng (Jason) Song, a major inventor of ITE technologies and Chief Scientific Officer of the company. The University of Wisconsin-Madison science team is led by Dr. Jing Zheng, associate professor of Obstetrics and Gynecology. Other authors of the paper are Kai Wang, Yan Li, Yizhou Jiang, Caifeng Dai, Manish S. Patankar. To access the paper, please follow this link: http://www.ncbi.nlm.nih.gov/pubmed/23851185.
For more information on AhR Pharmaceuticals, Inc., its technologies, and its research activities, please visit http://www.ahrpharma.com. For more information on University of Wisconsin-Madison, please visit http://www.wisc.edu.
AhR Pharmaceuticals, Inc. is devoted to the development of a novel natural hormone (for the Ah receptor) named ITE we discovered into an efficacious and sustainable but low side-effect therapeutic agent in intervention of cancer (with a possibility of eradication), obesity, and disorders related to imbalanced actions of immune systems.
# # #